Мodern Approaches to the Treatment and Prevention of Recurrent of Ophthalmic Herpes. Review
https://doi.org/10.18008/1816-5095-2019-1S-12-20
Abstract
The review focuses on modern treatment aspects and prevention of ophthalmic herpes.
The generalized experience of the clinical nucleoside administration, the basic antiviral drugs in the treatment of this pathology, is presented in detail. Information about indications, side effects and various schemes for their systemic and local application is provided. Questions on the duration of nucleoside administration in various clinical forms of eye herpes are considered. A meta-analysis of the comparative therapeutic nucleoside efficacy based on the results of more than 100 placebo-controlled randomized trials is presented. Special attention is paid to the rare but severe eye pathology, the acute retinal necrosis. Also data on the indications and contraindications of corticosteroids and on the current view of immunotherapy of ophthalmic herpes is presented. The question of the modern approach to the disease prevention recurrences is considered in detail, particularly, the results of the nucleoside administration have a high level of evidence, and, herpetic vaccines in the rehabilitation of patients with herpes infection are not widely used due to the lack of reliable methods for evaluating the efficacy. The information on the search for new effective drugs that have a targeted effect on certain patient cell receptors that can inhibit the penetration and spread of the herpes virus that can cause a controlled immune response is provided. Expanding the arsenal of effective and safe antiviral therapy will definitely optimize the treatment of ophthalmic herpes and prevent the occurrence of its recurrence and severe outcomes.
About the Author
G. Ch. Zaynutdinova
Ufa Eye Research Institute
Russian Federation
Russian Federation
MD, Senior Researcher of Scientific and Educational Department
Pushkin str., 90, Ufa, 450008, Russian Federation
References
1. Sharma S., Mulik S. , Kumar N., Suryawanshi A., Rouse B.T. An anti-inflammatory role of VEGFR2/Src kinase inhibitor in herpes simplex virus 1-induced immunopathology. J. Virol. 2011;85(12):5995–6007. doi: 10.1128/JVI.00034-11
2. Maychuk Yu.F. Successes and problems of pharmacotherapy of infectious and allergic diseases of the eye. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2000;1:13–15 (In Russ.).
3. Gimenez F., Mulik S. , Veiga-Parga T. , Bhela S., Rouse B.T. Robo 4 counteracts angiogenesis in herpetic stromal keratitis. PLoS One. 2015;10(12): Article e0141925. DOI: 10.1371/journal.pone.0141925
4. Kasparov A.A. Current aspects of the treatment of herpes viral keratitis. Annals of Ophthalmology = Vestnik oftal’mologii. 2000;116(1):59–61 (In Russ.).
5. Maychuk Yu.F. The state and prospects of pharmacotherapy of infectious and allergic diseases of the eye. Annals of Russian academy of medical sciences = Vestnik Rossiyskoy akademii meditsinskikh nauk. 2003;5:23–28 (In Russ.).
6. Kasparov A.A. Treatment of herpes keratitis. Yesterday Today Tomorrow. Refractive surgery and ophthalmology = Refraktsionnaya khirurgiya i oftal’mologiya. 2005;5(4):31 (In Russ.).
7. Farooq A.V., Shukla, D. Herpes Simplex Epithelial and Stromal Keratitis: An Epidemiologic Update. Surv. Ophthalmol. 2012;57(5):448–462. DOI: 10.1016/j.survophthal.2012.01.005
8. Young R.C., Hodge D.O., Liesegang T.J., Baratz K.H. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976–2007: the effect of oral antiviral prophylaxis. Arch Ophthalmol. 2010;128(9):1178–1183. DOI: 10.1001/archophthalmol.2010.187
9. Kaufman H.E. Treatment of viral diseases of the cornea and external eye. Prog. Retin. Eye Res. 2000;19(1):69–85.
10. Kothari M.T., Mehta B.K., Asher N.S., Kothari K.J. Recurrence of bilateral herpes simplex virus keratitis following bimatoprost use. Indian. J. Ophthalmol. 2006;54(1): 47–48.
11. Miyajima S., Sano Y., Sotozono C., Yokoi N., Ishino Y., Kinoshita S. Herpes simplex keratitis after ophthalmic surgery. Nippon Ganka Gakkai Zasshi. 2003;107(9):538–542.
12. Kamburoğlu G., Ertan A, Bahadir M. Implantation of Artisan toric phakic intraocular lens following Intacs in a patient with keratoconus. J. Cataract. Refract. Surg. 2007; 33(3):528–530. DOI: 10.1016/j.jcrs.2006.10.047
13. Jain V., Pineda R. Reactivated herpetic keratitis following laser in situ keratomileusis. J Cataract Refract Surg. 2009;35(5):946–948. DOI: 10.1016/j.jcrs.2008.11.065
14. Zhilyakova E.T., Novikova M.Yu. Novikov O.O., Tkacheva A.S., Pridachina D.V. Study of the range of antiviral eye dosage forms. Belgorod State University Scientific Bulletin = Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. 2012;1:179–183 (In Russ.).
15. Yin M.T., James C.M., Brust H.V.T., Hammer S.M. Clinical Virology. 3rd Edition ASM Press, Washington D.C., USA. 2009;217–264.
16. Elion, G.B., Furman, P.A., Fyfe, J.A., de Miranda, P., Beauchamp, L., Schaeffer, H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proceedings of the National Academy of Sciences of the United States of America. 1977;74:5716–5720.
17. Tsatsos M., MacGregor C., Athanasiadis I., Moschos M.M., Hossain P., Anderson D. Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents. Clin Exp Ophthalmol. 2016;44(9):824–837. DOI: 10.1111/ceo.12785
18. Croxtall J.D. Ganciclovir ophthalmic gel 0.15 %: in acute herpetic keratitis (dendritic ulcers). Drugs. 2011;26(71):603–610. DOI: 10.2165/11207240-000000000-00000
19. Kaufman H.E., Haw W.H. Ganciclovir ophthalmic gel 0.15 %: safety and efficacy of a new treatment for herpes simplex keratitis. Curr. Eye Res. 2012;37:654–660. DOI: 10.3109/02713683.2012.692846
20. Chou T.Y., Hong B.Y. Ganciclovir ophthalmic gel 0.15 % for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. Ther. Clin. Risk. Manag. 2014;10:665–681. DOI: 10.2147/TCRM.S58242
21. Thackray A.M., Field H.J. Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type 1 latency in mice: a quantitative study. Antimicrobial agents and chemotherapy. 1998;42:1555–1562.
22. Aizman A.I., Johnson M.W., Elner S.G. Treatment of acute retinal necrosis syndrome with oral antiviral medications. Ophthalmol. 2007;114(2):307–312. DOI: 10.1016/j.ophtha.2006.06.058
23. Colin J. Ganciclovir ophthalmic gel, 0.15 %: a valuable tool for treating ocular herpes. Clin. Ophthalmol. 2007;1:441–453.
24. Hobden J.A., Kumar M.J.A., Kaufman H.E., Clement C., Varnell E.D., Bhattacharjee P.S., Hill J.M. In vitro synergism of trifluorothymidine and ganciclovir against HSV-1. Invest. Ophthalmol. Vis. Sci. 2011;52(2):830–833. DOI: 10.1167/iovs.10-5671
25. Wilhelmus K.R. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev. 2015;1:CD002898. Published online. DOI: 10.1002/14651858.CD002898.pub5
26. Barron B.A., Gee L., Hauck W.W., Kurinij N., Dawson C.R., Jones D.B., Wilhelmus K.R., Kaufman H.E., Sugar J., Hyndiuk R.A. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Оphthalmology. 1994;101(12):1871–1882.
27. Komoto S., Higaki S., Fukuda M., Shimomura Y. Effects of antiviral medications on herpetic epithelial keratitis in mice. Jpn. J. Ophthalmol. 2015;59(3):194–200. DOI: 10.1007/s10384-015-0375-3
28. Collum L.M., McGettrick P., Akhtar J., Lavin J., Rees P.J. Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration. Br J Ophthalmol. 1986;70:435–438.
29. Shilova N.P., Baikova I.A., Kurs O.V. Personal features of patients with recurrent herpes simplex. Medical and biological problems of life = Mediko-biologicheskie problemy zhiznedeyatel’nosti. 2011;2(6):108–113 (In Russ.).
30. Wang J.C., Dahl A.A. Herpes Simplex Keratitis. Мediscape. 2016.
31. Shimomura Y. Battle with herpes for 37 years. Nippon Ganka Gakkai Zasshi. 2015;119(3):145–166; discussion 167.
32. Hung S.O., Patterson A., Rees P.J. Pharmacokinetics of oral acyclovir (Zovirax) in the eye. Br. J. Ophthalmol. 1984;68:192–195.
33. Huynh T.H., Johnson M.W., Comer G.M., Fish D.N. Vitreous penetration of orally administered valacyclovir. Am. J. Ophthalmol. 2008;145:682–686. DOI: 10.1016/j.ajo.2007.11.016
34. Tsatsos M., MacGregor C., Athanasiadis I., Moschos M.M., Hossain P., Anderson D. Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents. Clin Exp Ophthalmol. 2016;44(9):824–837. DOI: 10.1111/ceo.12785
35. Van Velzen M., van de Vijver D.A., van Loenen F.B., Osterhaus A.D., Remeijer L., Verjans G.M. Acyclovir prophylaxis predisposes to antiviral resistant recurrent herpetic keratitis. J. Infect. Dis. 2013;208:1359–1365. DOI: 10.1093/infdis/jit350
36. Andrei G., Georgala A., Topalis D., Fiten P., Aoun M., Opdenakker G., Snoeck R. Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy. The J. of infectious diseases. 2013;207:1295–1305.DOI: 10.1093/infdis/jit019
37. Miserocchi E., Modorati G., Galli L., Rama P. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. Am. J. Ophthalmol. 2007;144:547–551. DOI: 10.1016/j.ajo.2007.06.001
38. Weiner G. Demystifying the Ocular Herpes Simplex Virus. EyeNet. 2013;41–46.
39. Young R.C., Hodge D.O., Liesegang T.J., Baratz K.H. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976–2007: the effect of oral antiviral prophylaxis. Arch Ophthalmol. 2010;128:1178–1183. DOI: 10.1001/archophthalmol.2010.187
40. Hsiao C.H, Yeung L., Yeh L.K., Kao L.Y., Tan H.Y., Wang N.K., Lin K.K., Ma D.H. Pediatric herpes simplex virus keratitis. Cornea. 2009;28(3):249–253. DOI: 10.1097/ICO.0b013e3181839aee
41. Reddy J.C., Rapuano C.J. Current Concepts in the Management of Herpes Simplex Anterior Segment Eye Disease. C.J. Curr. Ophthalmol. Rep. 2013;1:194–203. DOI: 10.1007/s40135-013-0024-2
42. Garcia D.D., Farjo Q., Musch D.C., Sugar A. Effect of prophylactic oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea. 2007;26:930–934. DOI: 10.1097/ICO.0b013e3180e79b77
43. Seitz B., Heiligenhaus A. Herpetic keratitis. Various expressions require different therapeutic approaches. Ophthalmologe. 2011;108(4):385–395; quiz 396–397. DOI: 10.1007/s00347-011-2346-5
44. Kaufman H.E. Can we prevent recurrences of herpes infections without antiviral drugs? Invest. Ophthalmol.Vis. Sci. 2002;43(5):1325–1329.
45. Bettahi I., Nesburn A.B., Yoon S., Zhang X., Mohebbi A., Sue V., Vanderberg A., Wechsler S.L., BenMohamed L. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest. Ophthalmol. Vis. Sci. 2007;48:4643–4653. DOI: 10.1167/iovs.07-0356
46. Barinsky I.F., Alimbarovova L.M., Lazarenko A.A., Mahmudov F.R., Sergeev O.V.. Vaccines as a means of specific immunocorrection in case of herpetic infections. Problems of virology = Voprosy virusologii. 2014;59(1):5–11 (in Russ.).
47. Naurskaya E.V., Zaitseva A.G., Kobets N.V., Alimbarova L.M., Barinsky I.F. Features of the functional state of the peritoneal macrophages of mice, sensitive and stable lines during intravaginal infection with herpes simplex virus type 2 and mucosal vaccination. Experimental Biology and Medicine = Byulleten’ ehksperimental’noj biologii i mediciny. 2008;145(2):196–200 (In Russ.).
48. Hu K., Malla T., Zhai Y., Dong L., Tang R. Topical Administration Is a Promising Inoculating Route versus Intramuscular Inoculation for the Nanoparticle-Carried DNA Vaccine to Prevent Corneal Infections. Ophthalmic Res. 2015;55(2):99–110. DOI: 10.1159/000441898
49. Royer D.J., Gurung H.R., Jinkins J.K., Geltz J.J., Wu J.L., Halford W.P., Carr D. J.J., Longnecker R.M. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity. J. Virol. 2016;90(11):5514–5529. DOI: 10.1128/JVI.00517-16
50. Barinsky I.F., Kasparov A.A., Lazarenko A.A. Inactivated vaccine against herpes simplex viruses of the 1st and 2nd types as a means of immune correction in chronic herpes infection. Journal of Microbiology, Epidemiology and Immunobiology = ZHurnal mikrobiologii, ehpidemiologii i immunobiologii. 1999;6:98–102 (In Russ.).
51. Sugita S., Shimizu N., Watanabe K., Mizukami M., Morio T., Sugamoto Y., Mochizuki M. Use of multiplex PCR and real-time PCR to detect human herpes virus genome in ocular fluids of patients with uveitis. Br. J. Ophthalmol. 2008;92(7):928–932. DOI: 10.1136/bjo.2007.133967
52. Wilhelmus K.R. , Gee L., Hauck W.W., Kurinij N., Dawson C.R., Jones D.B., Barron B.A., Kaufman H.E., Sugar J., Hyndiuk R.A. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmol. 1994;101(12):1883–1895; discussion 1895–1886.
53. Pleyer U., Chee S.-P. Current aspects on the management of viral uveitis in immunocompetent individuals. Clin Ophthalmol. 2015;9:1017–1028. DOI: 10.2147/OPTH.S60394
54. Heiligenhaus A., Steuhl K.P. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch. Clin. Exp. Ophthalmol. 1999;237(5):435–438.
55. Rao S.N. Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1 % with topical cyclosporine 0.05 %. Am. J. Ophthalmol. 2006;141(4):771–772. DOI: 10.1016/j.ajo.2005.11.042
56. Knickelbein J.E., Hendricks R.L., Charukamnoetkanok P. Management of herpes simplex virus stromal keratitis: an evidence-based review. Surv. Ophthalmol. 2009;54(2):226–234. DOI: 10.1016/j.survophthal.2008.12.004
57. Vinores S.A., Derevjanik N.L., Shi A., Vinores M.A., Klein D.A., Whittum-Hudson J.A. Vascular endothelial growth factor (VEGF), transforming growth factorbeta (TGFbeta), and interleukin-6 (IL-6) in experimental herpes virus retinopathy: association with inflammation and viral infection. Histol. Histopathol. 2001;16(4):1061–1071. DOI: 10.14670/HH-16.1061
58. Shah A.M., Oster S.F., Freeman W.R. Viral retinitis after intravitreal triamcinolone injection in patients with predisposing medical comorbidities. Am. J. Ophthalmol. 2010;149(3):433–440. DOI: 10.1016/j.ajo.2009.10.019
59. Chang S., Weissgold D.J., Singer J.A., Sobrin L. Acute retinal necrosis after intraocular triamcinolone acetonide injection. Retin. Cases Brief. Rep. 2010;4(4):306–308. DOI: 10.1097/ICB.0b013e3181b5ee58
60. Wong R.W., Jumper J.M., McDonald H.R., Johnson R.N., Fu A., Lujan B.J., Cunningham E.T.Jr. Emerging concepts in the management of acute retinal necrosis. Postgrad Med J. 2013;89(1054):478–485. DOI: 10.1136/postgradmedj-2012-301983rep
61. Malkhanov V.B., Zaynutdinova G.Kh., Shevchuk N.E. The effectiveness of the drug Panavir with anterior uveitis of rheumatic rubric. Annals of Orenburg State University = Vestnik Orenburgskogo gosudarstvennogo universiteta. 2011;14:235–238 (In Russ.).
62. Bikbov M.M., Shevchuk N.E.,Malkhanov V.B., Zainutdinova G.H. Herpetic eye disease. Clinical picture. Diagnosis.Treatment. Ufa: Gilem publ., 2016:168 (In Russ.)].
63. Guliyeva M.G. The effectiveness of ophthalmoferon in the combined antiviral treatment of severe stromal herpetic keratitis. Refractive surgery and ophthalmology = Refraktsionnaya khirurgiya i oftal’mologiya. 2006;4:48–52 (In Russ.).
64. Wilhelmus K.R. Therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database. Syst. Rev. 2007. CD002898. DOI: 10.1002/14651858.CD002898.pub3
65. Elbadawy H.M., Gailledrat M., Desseaux C., Ponzin D., Ferrari S. Targeting Herpetic keratitis by Gene Therapy. J. of Ophthalmology. 2012; ID 594869:14. DOI: 10.1155/2012/594869
66. Kasparov A.A., Pereverzina, O.K. Gorbovitskaya G.E. New in the combined drug therapy (poludan + acyclovir) of various manifestations of ophthalmic herpes. Journal of Ophthalmology (Ukraine) = Ovtal’mologitscheckij zhurnal. 1991;4:196–200 (In Russ.).
67. Maychuk Yu.F., Kazachenko M.A., Shchipanova A.I., Andzhelov V.O., Krichevskaya G.I.. Likopid immunomodulator in the treatment of herpetic stromal keratitis. Annals of Ophthalmology = Vestnik oftal’mologii. 1997;4:23–26 (In Russ.).
68. Parkhomenko T.G., Mats A.N. Affinoleukin Immunotherapy. Attending doctor = Lechashchij vrach. 2000;8:42–44 (In Russ.).
69. Malkhanov V.B., Shevchuk N.E., Zaynutdinova G.Kh., Marvanova Z.R. The rationale for the use of cycloferon and testosterone in the treatment of herpetic keratitis in men. Journal of Ophthalmology (Ukraine) = Ovtal’mologitscheckij zhurnal. 2007;419(6):12–15 (In Russ.).
70. Velichko T.V., Lebedev V.V., Katargina L.A., Slepova O.S. Correction of an atypical response to steroid therapy in children with immunoinflammatory diseases. Allergology and immunology = Allergologiya i immunologiya. 2013;(2):34–37 (in Russ.).
71. Zainutdinova G.H., Malkhanov V.B. The use of testosterone in the complex treatment of herpetic keratitis severe forms in males. Annals of Ophthalmology = Vestnik oftalmologii. 2004;120(3):24–26 (In Russ.).
72. Zainutdinova G.H., Malkhanov V.B. The relationship of hormone and immunological disruptions in herpes herpetic keratitis in males. Problems of virology = Voprosy virusologii. 2004;(2):30–32 (In Russ.).
73. Samgin M.A., Khaldin A.A. Herpes simplex: dermatological aspects. Moscow: MED-pressform; 2002 (In Russ.).
74. Andrei G., Snoeck R. Herpes simplex virus drug-resistance: new mutations and insights. Curr. Opin. Infect. Dis. 2013;26(6):551–560. DOI: 10.1097/QCO.0000000000000015
75. Piret J., Boivin G. Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Curr. Opin. Infect. Dis. 2016;29(6):654–662. DOI: 10.1097/QCO.0000000000000288
76. Liang Y., Vogel J.L, Narayanan A., Peng H., Kristie T.M. Inhibition of the histone demethylase LSD1 blocks α-herpesvirus lytic replication and reactivation from latency. Manuscript in review. 2009. DOI: 10.1038/nm.2051
77. Kristie T.M., Liang Y., Vogel J.L. Control of alpha-herpesvirus IE gene expression by HCF-1 coupled chromatin modification activities. Biochim. Biophys. Acta. 2010;1799(3–4):257–265. doi: 10.1016/j.bbagrm.2009.08.003
78. Park P.J., Antoine T.E., Farooq A.V., Valyi-Nagy T., Shukla D. An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection. Investig Ophthalmol. Vis. Sc. 2013;54(9):6373–6381. DOI: 10.1167/iovs.13-12832
79. Jaishankar D., Buhrman J.S., Valyi-Nagy T., Gemeinhart R.A., Shukla D. Extended release of an anti-heparan sulfate peptide from a contact lens suppresses corneal herpes simplex virus-1 infection. Investig Ophthalmol. Vis. Sci. 2016;57(1):169–180. DOI: 10.1167/iovs.15-18365
80. Yadavalli T., Agelidis A., Jaishankar D., Mangano K., Thakkar N., Penmetcha K., Shukla D. Targeting herpes simplex virus-1 gD by a DNA aptamer can Be an effective new strategy to curb viral infection. Mol. Ther Nucleic. Acids. 2017;9:365–378. DOI: 10.1016/j.omtn.2017.10.009
81. Agelidis A.M., Hadigal S.R., Jaishankar D., Shukla D. Viral activation of heparanase drives pathogenesis of herpes simplex virus-1. Cell Rep. 2017;20(2):439–450. DOI: 10.1016/j.celrep.2017.06.041
82. Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–821. DOI: 10.1126/science.1225829
83. van Diemen F.R., Kruse E.M., Hooykaas M.J., Bruggeling C.E., Schürch A.C., van Ham P.M, Imhof S.M., Nijhuis M., Wiertz E.J., Lebbink R.J. CRISPR/Cas9-Mediated genome editing of herpesviruses limits productive and latent infections. PLoS Pathog. 2016;12(6):Article e1005701. DOI: 10.1371/journal.ppat.1005701
84. Mulik S., Xu J., Reddy P.B., Rajasagi N.K., Gimenez F., Sharma S., Lu P.Y., Rouse B.T. Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus. Am J. Pathol. 2012;181(2):525–534. DOI: 10.1016/j.ajpath.2012.04.014
85. Sharma S., Mulik S. , Kumar N., Suryawanshi A., Rouse B.T. An anti-inflammatory role of VEGFR2/Src kinase inhibitor in herpes simplex virus 1-induced immunopathology. J. Virol. 2011;85(12):5995–6007. doi: 10.1128/JVI.00034-11
86. Gimenez F., Mulik S. , Veiga-Parga T. , Bhela S., Rouse B.T. Robo 4 counteracts angiogenesis in herpetic stromal keratitis. PLoS One. 2015;10(12): Article e0141925. DOI: 10.1371/journal.pone.0141925
Review
For citations:
Zaynutdinova G.Ch. Мodern Approaches to the Treatment and Prevention of Recurrent of Ophthalmic Herpes. Review. Ophthalmology in Russia. 2019;16(1S):12-20. (In Russ.) https://doi.org/10.18008/1816-5095-2019-1S-12-20
Views:
3072
Email this article 